Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry).
Enhanced external counterpulsation (EECP) is a noninvasive circulatory assist device that has recently emerged as a treatment option for refractory angina in left ventricular (LV) dysfunction. This 2-year cohort study describes the long-term follow-up of patients who had severe LV dysfunction that was treated with EECP for angina pectoris and reports clinical outcomes, event-free survival rates, and the incidence of repeat EECP. This study included 363 patients who had refractory angina and LV ejection fraction < or =35%. Most patients reported quality of life as poor. After completion of treatment, there was a significant decrease in severity of angina class (p < 0.001), and 72% improved from severe angina to no angina or mild angina. Fifty-two percent of patients discontinued nitroglycerin use. Quality of life improved substantially. At 2 years this decrease in angina was maintained in 55% of patients. The 2-year survival rate was 83%, and the major adverse cardiovascular event-free survival rate was 70%. Forty-three percent had no reported cardiac hospitalization; 81% had no reported congestive heart failure events. Repeat EECP was performed in 20% of these patients. The only significant independent predictor of repeat EECP in a proportional hazard model was failure to complete the first EECP treatment course (hazard ratio 2.9, 95% confidence interval 1.7 to 4.9). Improvements in angina symptoms and quality of life were maintained at 2 years. In conclusion, for patients who have high-risk LV dysfunction, EECP offers an effective, durable therapeutic approach for refractory angina. Decreased angina and improvement in quality of life were maintained at 2 years, with modest repeat EECP and low major cardiovascular event rates.
Soran
Ozlem
O
Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. soranzo@upmc.edu
Kennard
Elizabeth D
ED
Kfoury
Abdallah Georges
AG
Kelsey
Sheryl F
SF
D000368:Aged; D000787:Angina Pectoris / Q000401:mortality / Q000628:therapy*; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000453:epidemiology; D015908:Counterpulsation; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000453:epidemiology; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D016016:Proportional Hazards Models; D011788:Quality of Life; D012042:Registries; D019233:Retreatment / Q000706:statistics & numerical data; D012720:Severity of Illness Index; D013318:Stroke Volume; D016896:Treatment Outcome; D016312:Treatment Refusal / Q000706:statistics & numerical data; D018487:Ventricular Dysfunction, Left / Q000401:mortality / Q000628:therapy*